Iranian Journal of Pediatrics

Published by: Kowsar

Risperidone Versus Methylphenidate in Treatment of Preschool Children With Attention-Deficit Hyperactivity Disorder

Fariba Arabgol 1 , * , Leily Panaghi 2 and Vahid Nikzad 3
Authors Information
1 Behavioral Science Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Family Research Institute, Shahid Beheshti University, Tehran, IR Iran
3 Bronx-Lebanon Hospital Center, Albert Einstein College of Medicine, New York, USA
Article information
  • Iranian Journal of Pediatrics: February 28, 2015, 25 (1)
  • Published Online: February 21, 2015
  • Article Type: Research Article
  • Received: September 11, 2014
  • Revised: December 1, 2014
  • Accepted: January 10, 2015
  • DOI: 10.5812/ijp.265

To Cite: Arabgol F, Panaghi L, Nikzad V. Risperidone Versus Methylphenidate in Treatment of Preschool Children With Attention-Deficit Hyperactivity Disorder, Iran J Pediatr. 2015 ; 25(1):-. doi: 10.5812/ijp.265.

Abstract
Copyright © 2015, Growth & Development Research Center.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
References
  • 1. Diagnostic and statistical manual of mental disorders. 2000;
  • 2. Arnold LE, Spetie L. Attention-Deficit/Hyperactivity Disorder. 2007;
  • 3. Waslick B, Greenhill L. Attention-deficit/Hyperactivity Disorder. 2004;
  • 4. Pliszka S, Aacap Work Group on Quality Issues . Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007; 46(7): 894-921[DOI][PubMed]
  • 5. Connor DF. Preschool attention deficit hyperactivity disorder: a review of prevalence, diagnosis, neurobiology, and stimulant treatment. J Dev Behav Pediatr. 2002; 23(1 Suppl)-9[PubMed]
  • 6. Wilens TE, Biederman J, Brown S, Tanguay S, Monuteaux MC, Blake C, Spencer TJ, et al. Psychiatric comorbidity and functioning in clinically referred preschool children and school-age youths with ADHD. J Am Acad Child Adolesc Psychiatry. 2002; 41(3): 262-8[DOI][PubMed]
  • 7. DuPaul GJ, McGoey KE, Eckert TL, VanBrakle J. Preschool children with attention-deficit/hyperactivity disorder: impairments in behavioral, social, and school functioning. J Am Acad Child Adolesc Psychiatry. 2001; 40(5): 508-15[DOI][PubMed]
  • 8. Tandon M, Si X, Luby J. Preschool onset attention-deficit/hyperactivity disorder: course and predictors of stability over 24 months. J Child Adolesc Psychopharmacol. 2011; 21(4): 321-30[DOI][PubMed]
  • 9. Gleason MM, Egger HL, Emslie GJ, Greenhill LL, Kowatch RA, Lieberman AF, Luby JL, Owens J, Scahill LD, Scheeringa MS, Stafford B, Wise B, Zeanah CH, et al. Psychopharmacological treatment for very young children: contexts and guidelines. J Am Acad Child Adolesc Psychiatry. 2007; 46(12): 1532-72[DOI][PubMed]
  • 10. Greenhill L, Kollins S, Abikoff H, McCracken J, Riddle M, Swanson J, McGough J, Wigal S, Wigal T, Vitiello B, Skrobala A, Posner K, Ghuman J, Cunningham C, Davies M, Chuang S, Cooper T, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry. 2006; 45(11): 1284-93[DOI][PubMed]
  • 11. Wigal T, Greenhill L, Chuang S, McGough J, Vitiello B, Skrobala A, Swanson J, Wigal S, Abikoff H, Kollins S, McCracken J, Riddle M, Posner K, Ghuman J, Davies M, Thorp B, Stehli A, et al. Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry. 2006; 45(11): 1294-303[DOI][PubMed]
  • 12. Kratochvil CJ, Vaughan BS, Stoner JA, Daughton JM, Lubberstedt BD, Murray DW, Chrisman AK, Faircloth MA, Itchon-Ramos NB, Kollins SH, Maayan LA, Greenhill LL, Kotler LA, Fried J, March JS, et al. A double-blind, placebo-controlled study of atomoxetine in young children with ADHD. Pediatrics. 2011; 127(4)-8[DOI][PubMed]
  • 13. Rappley MD, Mullan PB, Alvarez FJ, Eneli IU, Wang J, Gardiner JC. Diagnosis of attention-deficit/hyperactivity disorder and use of psychotropic medication in very young children. Arch Pediatr Adolesc Med. 1999; 153(10): 1039-45[PubMed]
  • 14. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA. 2000; 283(8): 1025-30[PubMed]
  • 15. Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1999; 38(12): 1551-9[DOI][PubMed]
  • 16. Scahill L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shepherd E, Arnsten AF, Cohen DJ, Leckman JF, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001; 158(7): 1067-74[PubMed]
  • 17. Klein-Schwartz W. Trends and toxic effects from pediatric clonidine exposures. Arch Pediatr Adolesc Med. 2002; 156(4): 392-6[PubMed]
  • 18. Gadow KD, Nolan EE. Differences between preschool children with ODD, ADHD, and ODD+ADHD symptoms. J Child Psychol Psychiatry. 2002; 43(2): 191-201[PubMed]
  • 19. Keenan K. Emotion Dysregulation as a Risk Factor for Child Psychopathology. Clin Psychol-Sci Pr. 2006; 7(4): 418-34[DOI]
  • 20. Schwebel DC, Speltz ML, Jones K, Bardina P. Unintentional injury in preschool boys with and without early onset of disruptive behavior. J Pediatr Psychol. 2002; 27(8): 727-37[PubMed]
  • 21. Wakschlag LS, Briggs-Gowan MJ, Carter AS, Hill C, Danis B, Keenan K, McCarthy KJ, Leventhal BL, et al. A developmental framework for distinguishing disruptive behavior from normative misbehavior in preschool children. J Child Psychol Psychiatry. 2007; 48(10): 976-87[DOI][PubMed]
  • 22. Loy JH, Merry SN, Hetrick SE, Stasiak K. Atypical antipsychotics for disruptive behaviour disorders in children and youths. Cochrane Database Syst Rev. 2012; 9[DOI][PubMed]
  • 23. Wilens TE, Biederman J, Brown S, Monuteaux M, Prince J, Spencer TJ. Patterns of psychopathology and dysfunction in clinically referred preschoolers. J Dev Behav Pediatr. 2002; 23(1 Suppl)-6[PubMed]
  • 24. Weiss M, Panagiotopoulos C, Giles L, Gibbins C, Kuzeljevic B, Davidson J, Harrison R, et al. A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic. J Child Adolesc Psychopharmacol. 2009; 19(5): 575-82[DOI][PubMed]
  • 25. Aman MG, Binder C, Turgay A. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol. 2004; 14(2): 243-54[DOI][PubMed]
  • 26. Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT. Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2004; 14(3): 372-94[DOI][PubMed]
  • 27. Reyes M, Croonenberghs J, Augustyns I, Eerdekens M. Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability. J Child Adolesc Psychopharmacol. 2006; 16(3): 260-72[DOI][PubMed]
  • 28. Ercan ES, Basay BK, Basay O, Durak S, Ozbaran B. Risperidone in the treatment of conduct disorder in preschool children without intellectual disability. Child Adolesc Psychiatry Ment Health. 2011; 5(1): 10[DOI][PubMed]
  • 29. Biederman J, Mick E, Hammerness P, Harpold T, Aleardi M, Dougherty M, Wozniak J, et al. Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry. 2005; 58(7): 589-94[DOI][PubMed]
  • 30. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry. 2000; 39(4): 509-16[DOI][PubMed]
  • 31. Dupaul GJ. Parent and Teacher Ratings of ADHD Symptoms: Psychometric Properties in a Community-Based Sample. J Clin Child Psychol. 1991; 20(3): 245-53[DOI]
  • 32. Conners CK. Conners Rating Scales. 1997;
  • 33. Correia Filho AG, Bodanese R, Silva TL, Alvares JP, Aman M, Rohde LA. Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation. J Am Acad Child Adolesc Psychiatry. 2005; 44(8): 748-55[DOI][PubMed]
  • 34. Gunther T, Herpertz-Dahlmann B, Jolles J, Konrad K. The influence of risperidone on attentional functions in children and adolescents with attention-deficit/hyperactivity disorder and co-morbid disruptive behavior disorder. J Child Adolesc Psychopharmacol. 2006; 16(6): 725-35[DOI][PubMed]
  • 35. Eapen V, Gururaj AK. Risperidone treatment in 12 children with developmental disorders and attention-deficit/hyperactivity disorder. Prim Care Companion J Clin Psychiatry. 2005; 7(5): 221-4[PubMed]
  • 36. Stadler C, Bolten M, Schmeck K. Pharmacotherapeutic intervention in impulsive preschool children: The need for a comprehensive therapeutic approach. Child Adolesc Psychiatry Ment Health. 2011; 5(1): 11[DOI][PubMed]
  • 37. Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Gebhardt N, Remschmidt H, Krieg JC, Hebebrand J, Theisen FM, et al. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J Psychiatr Res. 2009; 43(6): 620-6[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments